Fintepla®
![](/sites/default/files/2022-08/Fintepla_EU_Logo.png)
In the European Union and in the UK, Fintepla® is indicated for the treatment of seizures associated with Dravet syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.
Prescribing information Europe Sourced from https://www.ema.europa.eu
![](/sites/default/files/2022-08/Black%20triangle.png)
“This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions"
![](/sites/default/files/2022-08/Fintepla_US_logo.png)
In the US, FINTEPLA® is indicated for the treatment of seizures associated with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
Prescribing information USA (December 2023)
As of March 7, 2022, Zogenix Inc. and all its affiliates worldwide are part of the UCB Group of Companies.